Review

Drug-induced liver injury: insights from genetic studies

Raúl J Andrade

† Author for correspondence

Unidad de Hepatología, Departamento de Medicina, Facultad de Medicina, Boulevard Louis Pasteur 32, 29071 Málaga, Spain.

Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Málaga, Spain

Search for more papers by this author

Email the corresponding author at andrade@uma.es

Mercedes Robles

Unidad de Hepatología, Departamento de Medicina, Facultad de Medicina, Boulevard Louis Pasteur 32, 29071 Málaga, Spain.

Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Málaga, Spain

Search for more papers by this author

Email the corresponding author at andrade@uma.es

Eugenia Ulzurrun

Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Málaga, Spain

Clinical Pharmacology Service of the ‘Vírgen de la Victoria’ University Hospital, University of Málaga, Spain

Search for more papers by this author

M Isabel Lucena

Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Málaga, Spain

Clinical Pharmacology Service of the ‘Vírgen de la Victoria’ University Hospital, University of Málaga, Spain

Search for more papers by this author

Published Online:17 Sep 2009https://doi.org/10.2217/pgs.09.111

View article

Abstract

Drug-induced liver injury (DILI) is an increasing health problem and a challenge for physicians, regulatory bodies and the pharmaceutical industry, not only because of its potential severity and elusive pathogenesis but also because it is often inaccurately diagnosed, commonly missed entirely and more often not reported. The general view is that idiosyncratic DILI, which is not predictable whether based on the pharmacology of the drug or on the dose administered, is determined by the presence in the recipient of variants in, or expression of, genes coding for key metabolic pathways and/or the immune response, and the interaction of these genetic variants with environmental variables. Furthermore, idiosyncratic DILI is an example of a complex-trait disease with two or more susceptibility loci, as reflected by the frequency of genetic variants in the population often being higher than the occurrence of significant liver injury. Polymorphisms of bioactivation/toxification pathways via the CYP450 enzymes (Phase I), detoxification reactions (Phase II) and excretion/transport (Phase III), together with immunological factors that might determine DILI are reviewed. Challenges such as gene–trait association studies and whole-genome studies, and future approaches to the study of DILI are explored. Better knowledge of the candidate genes involved could provide further insight for the prospective identification of susceptible patients at risk of developing drug-induced hepatotoxicity, development of new diagnostic tools and new treatment strategies with safer drugs.

Keywords:

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

Bibliography

1 Ballet F: Hepatotoxicity in drug development: Detection, significance and solutions. J. Hepatol.26(Suppl. 2),26–36 (1997).Crossref, Medline, CAS, Google Scholar
2 Watkins PB, Whitcomb RW: Hepatic dysfunction associated with troglitazone. N. Engl. J. Med.338(13),916–917 (1998).Crossref, Medline, CAS, Google Scholar
3 Lee WM: Acute liver failure in the United States. Semin. Liver Dis.23(3),217–226 (2003).Crossref, Medline, CAS, Google Scholar
4 Temple R: Policy developments in regulatory approval. Stat. Med.21(19),2939–2948 (2002).Crossref, Medline, Google Scholar
5 Gunawan B, Kaplowitz N: Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev.36(2),301–312 (2004).Crossref, Medline, CAS, Google Scholar
6 Lucena MI, Andrade RJ, Kaplowitz N et al.: Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology49(6),2001–2009 (2009).Crossref, Medline, Google Scholar
7 Chalasani N, Fontana R, Bonkovsky MD et al.: Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology135(6),1924–1934 (2008).Crossref, Medline, Google Scholar
8 Zimmerman HJ: Hepatotoxicity. The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd Edition). Lippincott Williams & Wilkins, PA, USA (1999).Google Scholar
9 Park BK, Kitteringham NR, Maggs JL, Pirmohamed M, Williams DP: The role of metabolic activation in drug-induced hepatotoxicity. Annu. Rev. Pharmacol. Toxicol.45,177–202 (2005).Crossref, Medline, CAS, Google Scholar
10 Sgro C, Clinard F, Ouazir K et al.: Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology36(2),451–455 (2002).Crossref, Medline, Google Scholar
11 Meier Y, Cavallaro M, Roos M et al.: Incidence of drug-induced liver injury in medical inpatients. Eur. J. Clin. Pharmacol.61(2),135–143 (2005).Crossref, Medline, Google Scholar
12 Seguin B, Uetrecht J: The danger hypothesis applied to idiosyncratic drug reactions. Curr. Opin. Allergy Clin. Immunol.3(4),235–242 (2003).Crossref, Medline, Google Scholar
13 Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N: Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology47(6),2003–2009 (2008).Crossref, Medline, CAS, Google Scholar
14 Uetrecht J: Idiosyncratic drug reactions: current understanding. Annu. Rev. Pharmacol. Toxicol.47,513–539 (2007).Crossref, Medline, CAS, Google Scholar
15 De Abajo FJ, Montero D, Madurga M, Garcia Rodriguez LA: Acute and clinically relevant drug-induced liver injury: a population based case–control study. Br. J. Clin. Pharmacol.58(1),71–80 (2004).Crossref, Medline, Google Scholar
16 Senior JR: What is idiosyncratic hepatotoxicity? What is it not? Hepatology47(6),1813–1815 (2008).Crossref, Medline, Google Scholar
17 Boelsterli UA, Lim PL: Mitochondrial abnormalities. A link to idiosyncratic drug hepatotoxicity? Toxicol. Appl. Pharmacol.220(1),92–107 (2007).▪▪ Editorial proposing the mitochondrial threshold hypothesis, which is supported by a previous study from the same group demonstrating troglitazone-induced hepatic necrosis in heterozygous superoxide dismutase 2 gene knockout (Sod2+/-) mice.Crossref, Medline, CAS, Google Scholar
18 Kaplowitz N: Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov.4(6),489–499 (2005).Crossref, Medline, CAS, Google Scholar
19 DeLeve LD: Risk factors for drug-induced liver disease. In: Drug-Induced Liver Disease. Kaplowitz N, DeLeve LD (Eds)., Informa Healthcare, NY, USA, 291–305 (2007).Google Scholar
20 Andrade RJ, Lucena MI, Martín-Vivaldi R et al.: Acute liver injury associated with the use of ebrotidine, a new H₂-receptor antagonist. J. Hepatol.31(4),641–646 (1999).Crossref, Medline, CAS, Google Scholar
21 Lucena MI, Andrade RJ, Rodrigo L et al.: Trovafloxacin-induced acute hepatitis. Clin. Infect. Dis.30(2),400–401 (2000).Crossref, Medline, CAS, Google Scholar
22 Lucena MI, Carvajal A, Andrade RJ, Velasco A: Antidepressant-induced hepatotoxicity. Expert. Opin. Drug. Saf.2(3),249–262 (2003).Crossref, Medline, CAS, Google Scholar
23 Andrade RJ, Lucena MI, Alcantara R, Fraile JM: Bentazepam-associated chronic liver disease. Lancet343(8901),860 (1994).Crossref, Medline, CAS, Google Scholar
24 Spahn-Langguth H, Li C, Benet LZ: Mechanistic role of acyl glucuronides. In: Drug-Induced Liver Disease. Kaplowitz N, DeLeve LD (Eds)., Informa Healthcare, NY, USA, 125–157 (2007).Google Scholar
25 Berson A, De Beco V, Letteron P et al.: Steatohepatitis-inducing drugs cause mitochondrial dysfunction and lipid peroxidation in rat hepatocytes. Gastroenterology114(4),764–774 (1998).Crossref, Medline, CAS, Google Scholar
26 Pessayre D, Berson A, Fromenty B, Mansouri A: Mitochondria in steatohepatitis. Semin. Liver. Dis.21(1),57–69 (2001).Crossref, Medline, CAS, Google Scholar
27 Pessayre D, Haouzi D, Fau D, Robin MA, Mansouri A, Berson A: Withdrawal of life support, altruistic suicide, fratricidal killing and euthanasia by lymphocytes: different forms of drug-induced hepatic apoptosis. J. Hepatol.31(4),760–770 (1999).Crossref, Medline, CAS, Google Scholar
28 Kaplowitz N: Liver biology and pathobiology. Hepatology43(Suppl. 1),S235–S238 (2006).Crossref, Medline, CAS, Google Scholar
29 Fujimoto K, Kumagai K, Ito K et al.: Sensitivity of liver injury in heterozygous Sod2 knockout mice treated with troglitazone or acetaminophen. Toxicol. Pathol.37(2),193–200 (2009).Crossref, Medline, CAS, Google Scholar
30 Aithal GP: Genetic basis of idiosyncratic hepatotoxicity. In: Hepatotoxicity. Andrade RJ (Ed.), Permanyer Publications, Barcelona, Spain, 39–55 (2007).Google Scholar
31 Christensen K, Murray JC: What genome-wide association studies can do for medicine N. Engl. J. Med.356(11),1094–1096 (2007).Crossref, Medline, CAS, Google Scholar
32 Daly AK, Day CP: Candidate gene case–control association studies: advantages and potential pitfalls. Br. J. Clin. Pharmacol.52(5),489–499 (2001).Crossref, Medline, CAS, Google Scholar
33 Risch NJ: Searching for genetic determinants in the new millennium. Nature405(6788),847–856 (2000).Crossref, Medline, CAS, Google Scholar
34 Maddrey WC: Drug-induced hepatotoxicity. J. Clin. Gastroenterol.39(4 Suppl. 2),S83–S89 (2005).Crossref, Medline, Google Scholar
35 Pirmohamed M: Genetic factors in the predisposition to drug-induced hypersensitivity reactions. AAPS J.8(1),E20–E26 (2006).Crossref, Medline, CAS, Google Scholar
36 Gillette JR: Keynote address: man, mice, microsomes, metabolites, and mathematics 40 years after the revolution. Drug Metab. Rev.27(1–2),1–44 (1995).Crossref, Medline, CAS, Google Scholar
37 Pessayre D: Role of reactive metabolites in drug-induced hepatitis. J. Hepatol.23(Suppl. 1),16–24 (1995).Crossref, Medline, CAS, Google Scholar
38 Williams DP, Kitteringham NR, Naisbitt DJ, Pirmohamed M, Smith DA, Park BK: Are chemically reactive metabolites responsible for adverse reactions to drugs? Curr. Drug Metab.3(4),351–366 (2002).Crossref, Medline, CAS, Google Scholar
39 Walgren JL, Mitchell MD, Thompson DC: Role of metabolism in drug-induced idiosyncratic hepatotoxicity. Crit. Rev. Toxicol.35(4),325–361 (2005).Crossref, Medline, CAS, Google Scholar
40 Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W: Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA286(18),2270–2279 (2001).Crossref, Medline, CAS, Google Scholar
41 Xu C, Li CY, Kong AN: Induction of Phase I, II and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res.28(3),249–268 (2005).Crossref, Medline, CAS, Google Scholar
42 Andrade RJ, Camargo R, Lucena MI, Gonzalez-Grande R: Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf.3(4),329–344 (2004).Crossref, Medline, CAS, Google Scholar
43 Larrey D: Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin. Liver Dis.22(2),145–155 (2002).Crossref, Medline, CAS, Google Scholar
44 Egger T, Dormann H, Ahne G et al.: Cytochrome p450 polymorphisms in geriatric patients: impact on adverse drug reactions – a pilot study. Drugs Aging22(3),265–272 (2005).Crossref, Medline, CAS, Google Scholar
45 Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmoller J: Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin. Pharmacokinet.44(12),1209–1225 (2005).Crossref, Medline, CAS, Google Scholar
46 Larrey D: Hepatotoxicity of herbal remedies. J. Hepatol.26(Suppl. 1),47–51 (1997).Crossref, Medline, CAS, Google Scholar
47 Horsmans Y, Lannes D, Pessayre D, Larrey D: Possible association between poor metabolism of mephenytoin and hepatotoxicity caused by Atrium, a fixed combination preparation containing phenobarbital, febarbamate and difebarbamate. J. Hepatol.21(6),1075–1079 (1994).Crossref, Medline, CAS, Google Scholar
48 Seybold U, Landauer N, Hillebrand S, Goebel FD: Senna-induced hepatitis in a poor metabolizer. Ann. Intern. Med.141(8),650–651 (2004).Crossref, Medline, Google Scholar
49 Miners JO, Birkett DJ: Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br. J. Clin. Pharmacol.45(6),525–538 (1998).Crossref, Medline, CAS, Google Scholar
50 Scordo MG, Aklillu E, Yasar U, Dahl ML, Spina E, Ingelman-Sundberg M: Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. Br. J. Clin. Pharmacol.52(4),447–450 (2001).Crossref, Medline, CAS, Google Scholar
51 De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA: Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol. Pharmacol.46(4),594–598 (1994).Medline, CAS, Google Scholar
52 Kirchheiner J, Brockmoller J: Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin. Pharmacol. Ther.77(1),1–16 (2005).Crossref, Medline, CAS, Google Scholar
53 Larrey D, Pageaux GP: Genetic predisposition to drug-induced hepatotoxicity. J. Hepatol.26(Suppl. 2),12–21 (1997).Crossref, Medline, CAS, Google Scholar
54 Sevilla-Mantilla C, Ortega L, Agundez JA, Fernandez-Gutierrez B, Ladero JM, Diaz-Rubio M: Leflunomide-induced acute hepatitis. Dig. Liver Dis.36(1),82–84 (2004).Crossref, Medline, CAS, Google Scholar
55 Morin S, Loriot MA, Poirier JM et al.: Is diclofenac a valuable CYP2C9 probe in humans? Eur. J. Clin. Pharmacol.56(11),793–797 (2001).Crossref, Medline, CAS, Google Scholar
56 Aithal GP, Day CP, Leathart JB, Daly AK: Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics10(6),511–518 (2000).Crossref, Medline, CAS, Google Scholar
57 Yasar U, Eliasson E, Forslund-Bergengren C et al.: The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro. Eur. J. Clin. Pharmacol.57(10),729–735 (2001).Crossref, Medline, CAS, Google Scholar
58 Bort R, Mace K, Boobis A et al.: Hepatic metabolism of diclofenac: role of human CYP in the minor oxidative pathways. Biochem. Pharmacol.58(5),787–796 (1999).Crossref, Medline, CAS, Google Scholar
59 Daly AK, Aithal GP, Leathart JBS, Swainsbury RA, Dang TS, Day CP: Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology132(1),272–281 (2007).▪ Elegant study showing that rather than being caused by just one single mutation it is a combination of several genetic variants that increases the risk for diclofenac hepatotoxicity.Crossref, Medline, CAS, Google Scholar
60 Kirchheiner J, Kudlicz D, Meisel C et al.: Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers. Clin. Pharmacol. Ther.74(2),186–194 (2003).Crossref, Medline, CAS, Google Scholar
61 Goldstein JA, Faletto MB, Romkes-Sparks M et al.: Evidence that CYP2C19 is the major (S)-mephenytoin 4´-hydroxylase in humans. Biochemistry33(7),1743–1752 (1994).Crossref, Medline, CAS, Google Scholar
62 Andersson T, Regardh CG, Lou YC, Zhang Y, Dahl ML, Bertilsson L: Polymorphic hydroxylation of S-mephenytoin and omeprazole metabolism in Caucasian and Chinese subjects. Pharmacogenetics2(1),25–31 (1992).Crossref, Medline, CAS, Google Scholar
63 Baumann P: Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test. Encephale12(4),143–148 (1986).Medline, CAS, Google Scholar
64 Ward SA, Walle T, Walle UK, Wilkinson GR, Branch RA: Propranolol’s metabolism is determined by both mephenytoin and debrisoquin hydroxylase activities. Clin. Pharmacol. Ther.45(1),72–79 (1989).Crossref, Medline, CAS, Google Scholar
65 Bertilsson L: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet.29(3),192–209 (1995).Crossref, Medline, CAS, Google Scholar
66 Allabi AC, Gala JL, Desager JP, Heusterspreute M, Horsmans Y: Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations. Br. J. Clin. Pharmacol.56(6),653–657 (2003).Crossref, Medline, CAS, Google Scholar
67 Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L: Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics5(6),358–363 (1995).Crossref, Medline, CAS, Google Scholar
68 Brosen K, de Morais SM, Meyer UA, Goldstein JA: A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics5(5),312–317 (1995).Crossref, Medline, CAS, Google Scholar
69 Pachkoria K, Lucena MI, Ruiz-Cabello F, Crespo E, Cabello MR, Andrade RJ: Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br. J. Pharmacol.150(6),808–815 (2007).Crossref, Medline, CAS, Google Scholar
70 Dorado P, Berecz R, Caceres MC, Gonzalez I, Cobaleda J, Llerena A: Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship. Clin. Chem. Lab. Med.43(3),275–279 (2005).Crossref, Medline, CAS, Google Scholar
71 Marez D, Legrand M, Sabbagh N et al.: Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics7(3),193–202 (1997).Crossref, Medline, CAS, Google Scholar
72 Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol.53(2),111–122 (2002).Crossref, Medline, CAS, Google Scholar
73 Morgan MY, Reshef R, Shah RR, Oates NS, Smith RL, Sherlock S: Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut25(10),1057–1064 (1984).Crossref, Medline, CAS, Google Scholar
74 Watson RG, Olomu A, Clements D, Waring RH, Mitchell S, Elias E: A proposed mechanism for chlorpromazine jaundice – defective hepatic sulphoxidation combined with rapid hydroxylation. J. Hepatol.7(1),72–78 (1988).Crossref, Medline, CAS, Google Scholar
75 Maurer HH, Kraemer T, Springer D, Staack RF: Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (ecstasy), piperazine, and pyrrolidinophenone types: a synopsis. Ther. Drug Monit.26(2),127–131 (2004).Crossref, Medline, CAS, Google Scholar
76 Caccia S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet.34(4),281–302 (1998).Crossref, Medline, CAS, Google Scholar
77 Otani K, Kaneko S, Tasaki H, Fukushima Y: Hepatic injury caused by mianserin. Br. Med. J.299(6697),519 (1989).Crossref, Medline, CAS, Google Scholar
78 Yasui N, Otani K, Kaneko S et al.: Inhibition of trazodone metabolism by thioridazine in humans. Ther. Drug Monit.17(4),333–335 (1995).Crossref, Medline, CAS, Google Scholar
79 Hull M, Jones R, Bendall M: Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. Br. Med. J.309(6951),378 (1994).Crossref, Medline, CAS, Google Scholar
80 Inoue K, Inazawa J, Nakagawa H et al.: Assignment of the human cytochrome P-450 nifedipine oxidase gene (CYP3A4) to chromosome 7 at band q22.1 by fluorescence in situ hybridization. Jpn. J. Hum. Genet.37(2),133–138 (1992).Crossref, Medline, CAS, Google Scholar
81 Nelson DR, Koymans L, Kamataki T et al.: P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics6(1),1–42 (1996).Crossref, Medline, CAS, Google Scholar
82 Hsieh KP, Lin YY, Cheng CL et al.: Novel mutations of CYP3A4 in Chinese. Drug Metab. Dispos.29(3),268–273 (2001).Medline, CAS, Google Scholar
83 Klees TM, Sheffels P, Thummel KE, Kharasch ED: Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5. Anesthesiology102(3),550–556 (2005).Crossref, Medline, CAS, Google Scholar
84 Staudinger JL, Goodwin B, Jones SA et al.: The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl Acad. Sci. USA98(6),3369–3374 (2001).Crossref, Medline, CAS, Google Scholar
85 Gnerre C, Blattler S, Kaufmann MR, Looser R, Meyer UA: Regulation of CYP3A4 by the bile acid receptor FXR: evidence for functional binding sites in the CYP3A4 gene. Pharmacogenetics14(10),635–645 (2004).Crossref, Medline, CAS, Google Scholar
86 Kostrubsky VE, Szakacs JG, Jeffery EH et al.: Role of CYP3A in ethanol-mediated increases in acetaminophen hepatotoxicity. Toxicol. Appl. Pharmacol.143(2),315–323 (1997).Crossref, Medline, CAS, Google Scholar
87 Lakehal F, Dansette PM, Becquemont L et al.: Indirect cytotoxicity of flucloxacillin toward human biliary epithelium via metabolite formation in hepatocytes. Chem. Res. Toxicol.14(6),694–701 (2001).Crossref, Medline, CAS, Google Scholar
88 Andrade RJ, Salmeron FJ, Lucena MI: Drug hepatotoxicity. In: The Clinician’s Guide to Liver Disease. Reddy KR, Faust T (Eds)., Slack Incorporated, NJ, USA, 321–343 (2005).Google Scholar
89 Kassahun K, Pearson PG, Tang W et al.: Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem. Res. Toxicol.14(1),62–70 (2001).Crossref, Medline, CAS, Google Scholar
90 Ricaurte B, Guirguis A, Taylor HC, Zabriskie D: Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann. Pharmacother.40(4),753–757 (2006).Crossref, Medline, Google Scholar
91 Lucena MI, Andrade RJ, Vicioso L, Gonzalez FJ, Pachkoria K, Garcia-Munoz B: Prolonged cholestasis after raloxifene and fenofibrate interaction: a case report. World J. Gastroenterol.12(32),5244–5246 (2006).Medline, Google Scholar
92 Chen B, Zhang WX, Cai WM: The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population. Eur. J. Clin. Pharmacol.62(5),355–359 (2006).Crossref, Medline, CAS, Google Scholar
93 Gross M, Kruisselbrink T, Anderson K et al.: Distribution and concordance of N-acetyltransferase genotype and phenotype in an American population. Cancer Epidemiol. Biomarkers Prev.8(8),683–892 (1999).Medline, CAS, Google Scholar
94 Evans DA: N-acetyltransferase. Pharmacol. Ther.42(2),157–234 (1989).Crossref, Medline, CAS, Google Scholar
95 Weber WW, Hein DW: N-acetylation pharmacogenetics. Pharmacol. Rev.37(1),25–79 (1985).Medline, CAS, Google Scholar
96 Agundez JA, Olivera M, Martinez C, Ladero JM, Benitez J: Identification and prevalence study of 17 allelic variants of the human NAT2 gene in a white population. Pharmacogenetics6(5),423–428 (1996).Crossref, Medline, CAS, Google Scholar
97 Lin HJ, Han CY, Lin BK, Hardy S: Ethnic distribution of slow acetylator mutations in the polymorphic N-acetyltransferase (NAT2) gene. Pharmacogenetics4(3),125–134 (1994).Crossref, Medline, CAS, Google Scholar
98 Xie HG, Xu ZH, Ou-Yang DS et al.: Meta-analysis of phenotype and genotype of NAT2 deficiency in Chinese populations. Pharmacogenetics7(6),503–514 (1997).Crossref, Medline, CAS, Google Scholar
99 Blum M, Grant DM, McBride W, Heim H, Meyer UA: Human arylamine N-acetyltransferase genes: isolation, chromosomal localization and functional expression. DNA Cell Biol.9(3),193–203 (1990).Crossref, Medline, CAS, Google Scholar
100 Hein DW, Doll MA, Rustan TD, Ferguson RJ: Metabolic activation of N-hydroxyarylamines and N-hydroxyarylamides by 16 recombinant human NAT2 allozymes: effects of 7 specific NAT2 nucleic acid substitutions. Cancer Res.55(16),3531–3536 (1995).Medline, CAS, Google Scholar
101 Huang YS, Chern HD, Su WJ et al.: Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis. Hepatology35(4),883–889 (2002).▪ Genotyping of NAT in Asian patients who are going to receive anti-TB hepatotoxicity may identify patients at risk.Crossref, Medline, CAS, Google Scholar
102 Ellard GA: Variations between individuals and populations in the acetylation of isoniazid and its significance for the treatment of pulmonary tuberculosis. Clin. Pharmacol. Ther.19(5 Pt 2),610–625 (1976).Crossref, Medline, CAS, Google Scholar
103 Lauterburg BH, Smith CV, Todd EL, Mitchell JR: Pharmacokinetics of the toxic hydrazino metabolites formed from isoniazid in humans. J. Pharmacol. Exp. Ther.235(3),566–570 (1985).Medline, CAS, Google Scholar
104 Sharma SK, Balamurugan A, Saha PK, Pandey RM, Mehra NK: Evaluation of clinical and immunogenetic risk factors for the development of hepatotoxicity during antituberculosis treatment. Am. J. Respir. Crit. Care Med.166(7),916–919 (2002).Crossref, Medline, Google Scholar
105 Mitchell JR, Thorgeirsson UP, Black M et al.: Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin. Pharmacol. Ther.18(1),70–79 (1975).Crossref, Medline, CAS, Google Scholar
106 Mitchell JR, Potter WZ: Drug metabolism in the production of liver injury. Med. Clin. North Am.59(4),877–885 (1975).Crossref, Medline, CAS, Google Scholar
107 Huang YS, Chern HD, Su WJ et al.: Cytochrome P450 2E1 genotype and the susceptibility to antituberculosis drug-induced hepatitis. Hepatology37(4),924–930 (2003).Crossref, Medline, CAS, Google Scholar
108 Olomu AB, Vickers CR, Waring RH et al.: High incidence of poor sulfoxidation in patients with primary biliary cirrhosis. N. Engl. J. Med.318(17),1089–1092 (1988).Crossref, Medline, CAS, Google Scholar
109 Knowles SR, Uetrecht J, Shear NH: Idiosyncratic drug reactions: the reactive metabolite syndromes. Lancet356(9241),1587–1591 (2000).Crossref, Medline, CAS, Google Scholar
110 Hayes JD, Flanagan JU, Jowsey IR: Glutathione transferases. Annu. Rev. Pharmacol. Toxicol.45,51–88 (2005).Crossref, Medline, CAS, Google Scholar
111 Ajith TA, Hema U, Aswathy MS: Zingiber officinale Roscoe prevents acetaminophen induced acute hepatotoxicity by enhancing hepatic antioxidant status. Food Chem. Toxicol.45(11),2267–2272 (2007).Crossref, Medline, CAS, Google Scholar
112 Gum SI, Jo SJ, Ahn SH et al.: The potent protective effect of wild ginseng (Panax ginseng C.A. Meyer) against benzo[a]pyrene-induced toxicity through metabolic regulation of CYP1A1 and GSTs. J. Ethnopharmacol.112(3),568–576 (2007).Crossref, Medline, CAS, Google Scholar
113 Henderson CJ, Wolf CR, Kitteringham N, Powell H, Otto D, Park BK: Increased resistance to acetaminophen hepatotoxicity in mice lacking glutathione S-transferase Pi. Proc. Natl Acad. Sci. USA97(23),12741–12745 (2000).Crossref, Medline, CAS, Google Scholar
114 Tanaka K, Kiyosawa N, Watanabe K, Manabe S: Characterization of resistance to bromobenzene induced hepatotoxicity by microarray. J. Toxicol. Sci.32(2),129–134 (2007).Crossref, Medline, CAS, Google Scholar
115 Morishita K, Mizukawa Y, Kasahara T et al.: Gene expression profile in liver of differing ages of rats after single oral administration of acetaminophen. J. Toxicol. Sci.31(5),491–507 (2006).Crossref, Medline, CAS, Google Scholar
116 Zhao P, Kalhorn TF, Slattery JT: Selective mitochondrial glutathione depletion byethanol enhances acetaminophen toxicity in rat liver. Hepatology36(2),326–335 (2002).Crossref, Medline, CAS, Google Scholar
117 Chan K, Han XD, Kan YW: An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. Proc. Natl Acad. Sci. USA98(8),4611–4616 (2001).Crossref, Medline, CAS, Google Scholar
118 Eaton DL, Bammler TK, Kelly EJ: Interindividual differences in response to chemoprotection against aflatoxin-induced hepatocarcinogenesis: implications for human biotransformation enzyme polymorphisms. Adv. Exp. Med. Biol.500,559–576 (2001).Crossref, Medline, CAS, Google Scholar
119 Dieckhaus CM, Roller SG, Santos WL, Sofia RD, Macdonald TL: Role of glutathione S-transferases A1–1, M1–1, and P1–1 in the detoxification of 2-phenylpropenal, a reactive felbamate metabolite. Chem. Res. Toxicol.14(5),511–516 (2001).Crossref, Medline, CAS, Google Scholar
120 Lo HW, Ali-Osman F: Genetic polymorphism and function of glutathione-S-transferases in tumor drug resistance. Curr. Opin. Pharmacol.7(4),367–374 (2007).Crossref, Medline, CAS, Google Scholar
121 Watanabe I, Tomita A, Shimizu M et al.: A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin. Pharmacol. Ther.73(5),435–455 (2003).Crossref, Medline, CAS, Google Scholar
122 Simon T, Becquemont L, Mary-Krause M et al.: Combined glutathione-S-transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity. Clin. Pharmacol. Ther.67(4),432–437 (2000).Crossref, Medline, CAS, Google Scholar
123 Green VJ, Pirmohamed M, Kitteringham NR, Knapp MJ, Park BK: Glutathione S-transferase µ genotype (GSTM1*0) in Alzheimer’s patients with tacrine transaminitis. Br. J. Clin. Pharmacol.39(4),411–415 (1995).Crossref, Medline, CAS, Google Scholar
124 De Sousa M, Pirmohamed M, Kitteringham NR, Woolf T, Park BK: No association between tacrine transaminitis and the glutathione transferase θ genotype in patients with Alzheimer’s disease. Pharmacogenetics8(4),353–355 (1998).Crossref, Medline, CAS, Google Scholar
125 Roy B, Chowdhury A, Kundu S et al.: Increased risk of antituberculosis drug-induced hepatotoxicity in individuals with glutathione S-transferase M1 null mutation. J. Gastroenterol. Hepatol.16(9),1033–1037 (2001).Crossref, Medline, CAS, Google Scholar
126 Huang YS, Su WJ, Huang YH et al.: Genetic polymorphisms of manganese superoxide dismutase, NAD(P)H:quinone oxidoreductase, glutathione-S-transferase M1 and T1, and the susceptibility to drug-induced liver injury. J. Hepatol.47(1),128–134 (2007).Crossref, Medline, CAS, Google Scholar
127 Lucena MI, Andrade RJ, Martínez C et al.: Glutathione-S-transferase M1 and T1 null genotypes as susceptibility factor for idiosyncratic drug-induced liver injury. Hepatology48(2),588–596 (2008).▪ Study demonstrating that the GST double null genotype acts as a general risk factor for idiosyncratic drug-induced liver injury.Crossref, Medline, Google Scholar
128 Sutton A, Khoury H, Prip-Buus C, Cepanec C, Pessayre D, Degoul F: The Ala16Val genetic dimorphism modulates the import of human manganese superoxide dismutase into rat liver mitochondria. Pharmacogenetics13(3),145–157 (2003).Crossref, Medline, CAS, Google Scholar
129 Dansette PM, Bonierbale E, Minoletti C et al.: Drug-induced immunotoxicity. Eur. J. Drug. Metab. Pharmacokinet.23(4),443–451 (1998).Crossref, Medline, CAS, Google Scholar
130 Mizutani T, Shinoda M, Tanaka Y et al.: Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2. Drug Metab. Rev.37(1),235–252 (2005).Crossref, Medline, CAS, Google Scholar
131 Gut J, Christen U, Frey N et al.: Molecular mimicry in halothane hepatitis: biochemical and structural characterization of lipoylated autoantigens. Toxicology97(1–3),199–224 (1995).Crossref, Medline, CAS, Google Scholar
132 Bourdi M, Tinel M, Beaune PH, Pessayre D: Interactions of dihydralazine with cytochromes P4501A: a possible explanation for the appearance of anti-cytochrome P4501A2 autoantibodies. Mol. Pharmacol.45(6),1287–1295 (1994).Medline, CAS, Google Scholar
133 Masubuchi Y, Horie T: Mechanism-based inactivation of cytochrome P450s 1A2 and 3A4 by dihydralazine in human liver microsomes. Chem. Res. Toxicol.12(10),1028–1032 (1999).Crossref, Medline, CAS, Google Scholar
134 Siegmund W, Franke G, Biebler KE et al.: The influence of the acetylator phenotype for the clinical use of dihydralazine. Int. J. Clin. Pharmacol. Ther. Toxicol.23(Suppl. 1),S74–S78 (1985).Medline, Google Scholar
135 Oude Elferink RP, Meijer DK, Kuipers F, Jansen PL, Groen AK, Groothuis GM: Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport. Biochim. Biophys. Acta.1241(2),215–268 (1995).Crossref, Medline, Google Scholar
136 Smith AJ, van Helvoort A, van Meer G et al.: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem.275(31),23530–23539 (2000).Crossref, Medline, CAS, Google Scholar
137 Konig J, Nies AT, Cui Y, Leier I, Keppler D: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta.1461(2),377–394 (1999).Crossref, Medline, CAS, Google Scholar
138 Cole SP, Bhardwaj G, Gerlach JH et al.: Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science258(5088),1650–1654 (1992).Crossref, Medline, CAS, Google Scholar
139 Grant CE, Kurz EU, Cole SP, Deeley RG: Analysis of the intron–exon organization of the human multidrug-resistance protein gene (MRP) and alternative splicing of its mRNA. Genomics45(2),368–378 (1997).Crossref, Medline, CAS, Google Scholar
140 Tsujii H, Konig J, Rost D, Stockel B, Leuschner U, Keppler D: Exon–intron organization of the human multidrug-resistance protein 2 (MRP2) gene mutated in Dubin–Johnson syndrome. Gastroenterology117(3),653–660 (1999).Crossref, Medline, CAS, Google Scholar
141 Mayer R, Kartenbeck J, Buchler M, Jedlitschky G, Leier I, Keppler D: Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes. J. Cell. Biol.131(1),137–150 (1995).Crossref, Medline, CAS, Google Scholar
142 Meier PJ, Stieger B: Molecular mechanisms in bile formation. News Physiol. Sci.15,89–93 (2000).Medline, CAS, Google Scholar
143 Meier PJ, Stieger B: Bile salt transporters. Annu. Rev. Physiol.64,635–661 (2002).Crossref, Medline, CAS, Google Scholar
144 Kullak-Ublick GA, Stieger B, Meier PJ: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology126(1),322–342 (2004).Crossref, Medline, CAS, Google Scholar
145 Awasthi CW, Awasthi S, Zimniak P: Multiple transport protein involved in the detoxification of endo- and xenobiotics. Front Biosci.15,427–437 (1997).Crossref, Google Scholar
146 Cantz T, Nies AT, Brom M, Hofmann AF, Keppler D: MRP2, a human conjugate export pump, is present and transports fluo 3 into apical vacuoles of Hep G2 cells. Am. J. Physiol. Gastrointest. Liver Physiol.278(4),G522–G531 (2000).Crossref, Medline, CAS, Google Scholar
147 Bolder U, Trang NV, Hagey LR et al.: Sulindac is excreted into bile by a canalicular bile salt pump and undergoes a cholehepatic circulation in rats. Gastroenterology117(4),962–971 (1999).Crossref, Medline, CAS, Google Scholar
148 Iverson SL, Uetrecht JP: Identification of a reactive metabolite of terbinafine: insights into terbinafine-induced hepatotoxicity. Chem. Res. Toxicol.14(2),175–181 (2001).Crossref, Medline, CAS, Google Scholar
149 Dietrich CG, de Waart DR, Ottenhoff R, Bootsma AH, van Gennip AH, Elferink RP: Mrp2-deficiency in the rat impairs biliary and intestinal excretion and influences metabolism and disposition of the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo. Carcinogenesis22(5),805–811 (2001).Crossref, Medline, CAS, Google Scholar
150 Choi JH, Ahn BM, Yi J et al.: MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics17(6),403–415 (2007).Crossref, Medline, CAS, Google Scholar
151 Trauner M, Meier PJ, Boyer JL: Molecular pathogenesis of cholestasis. N. Engl. J. Med.339(17),1217–1227 (1998).Crossref, Medline, CAS, Google Scholar
152 Dixon PH, Weerasekera N, Linton KJ et al.: Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Mol. Genet.9(8),1209–1217 (2000).Crossref, Medline, CAS, Google Scholar
153 Jacquemin E, Cresteil D, Manouvrier S, Boute O, Hadchouel M: Heterozygous non-sense mutation of the MDR3 gene in familial intrahepatic cholestasis of pregnancy. Lancet353(9148),210–211 (1999).Crossref, Medline, CAS, Google Scholar
154 De Vree JM, Jacquemin E, Sturm E et al.: Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis. Proc. Natl Acad. Sci. USA95(1),282–287 (1998).Crossref, Medline, CAS, Google Scholar
155 Rosmorduc O, Hermelin B, Poupon R: MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis. Gastroenterology120(6),1459–1467 (2001).Crossref, Medline, CAS, Google Scholar
156 Lang C, Meier Y, Stieger B et al.: Mutations and polymorphisms in the bile salt export pump and the multidrug resistance protein 3 associated with drug-induced liver injury. Pharmacogenet. Genomics17(1),47–60 (2007).Crossref, Medline, CAS, Google Scholar
157 Andrade RJ, Crespo E, Ulzurrun E et al.: Polymorphic bile salt export pump transporter is a major determinant of hepatocellular drug-induced liver injury. Hepatology48,468A (2008) (Abstract).Google Scholar
158 Leemann T, Transon C, Dayer P: Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4´-hydroxylation in human liver. Life Sci.52(1),29–34 (1993).Crossref, Medline, CAS, Google Scholar
159 Transon C, Lecoeur S, Leemann T, Beaune P, Dayer P: Interindividual variability in catalytic activity and immunoreactivity of three major human liver cytochrome P450 isozymes. Eur. J. Clin. Pharmacol.51(1),79–85 (1996).Crossref, Medline, CAS, Google Scholar
160 Tang W: The metabolism of diclofenac- enzymology and toxicology perspectives. Curr. Drug Metab.4(4),319–329 (2003).Crossref, Medline, CAS, Google Scholar
161 Boelsterli UA: Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Toxicol. Appl. Pharmacol.192(3),307–322 (2003).Crossref, Medline, CAS, Google Scholar
162 Aithal GP, Ramsay L, Daly AK et al.: Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology39(5),1430–1440 (2004).Crossref, Medline, CAS, Google Scholar
163 Njoku DB, Greenberg RS, Bourdi M et al.: Autoantibodies associated with volatile anesthetic hepatitis found in the sera of a large cohort of pediatric anesthesiologists. Anesth. Analg.94(2),243–249 (2002).Crossref, Medline, Google Scholar
164 Aithal GP: Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity. Expert. Opin. Drug Saf.3(6),519–523 (2004).Crossref, Medline, CAS, Google Scholar
165 Kaplowitz N: Drug-induced liver injury. Clin. Infect. Dis.38(Suppl. 2),S44–S48 (2004).Crossref, Medline, Google Scholar
166 Bourdi M, Masubuchi Y, Reilly TP et al.: Protection against acetaminophen-induced liver injury and lethality by interleukin 10: role of inducible nitric oxide synthase. Hepatology35(2),289–298 (2002).Crossref, Medline, CAS, Google Scholar
167 Masubuchi Y, Bourdi M, Reilly TP, Graf ML, George JW, Pohl LR: Role of interleukin-6 in hepatic heat shock protein expression and protection against acetaminophen-induced liver disease. Biochem. Biophys. Res. Commun.304(1),207–212 (2003).Crossref, Medline, CAS, Google Scholar
168 Bourdi M, Eiras DP, Holt MP et al.: Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury. Chem. Res. Toxicol.20(2),208–216 (2007).Crossref, Medline, CAS, Google Scholar
169 Pachkoria K, Lucena MI, Crespo E et al.: Analysis of IL-10, IL-4 and TNF-α polymorphisms in drug-induced liver injury (DILI) and its outcome. J. Hepatol.49(1),107–114 (2008).Crossref, Medline, CAS, Google Scholar
170 Carr DF, Alfirevic A, Tugwood JD et al.: Molecular and genetic association of interleukin-6 in tacrine-induced hepatotoxicity. Pharmacogenet. Genomics17(11),961–972 (2007).Crossref, Medline, CAS, Google Scholar
171 Hautekeete ML, Horsmans Y, van Waeyenberge C et al.: HLA association of amoxicillin-clavulanate – induced hepatitis. Gastroenterology117(5),1181–1186 (1999).▪ Pioneering study demonstrating an increased frequency of the DRB1*1501–DRB5*0101–DQB1*0602 haplotype in patients with cholestatic hepatitis related to amoxicillin-clavulanate.Crossref, Medline, CAS, Google Scholar
172 Daly AK, Donaldson PT, Bhatnagar P et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet.41(7),816–819 (2009).▪▪ Landmark study showing the power of a well-designed genome-wide association study to identify subjects susceptible to flucoxacillin induced drug-induced liver injury.Crossref, Medline, CAS, Google Scholar
173 Donaldson PT, Bhatnagar P, Graham J et al.: Susceptibility to drug-induced liver injury is determined by HLA class-II genotype. Hepatology48,464A (2008) (Abstract).Google Scholar
174 Mallal S, Nolan D, Witt C et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet359(9308),727–732 (2002).Crossref, Medline, CAS, Google Scholar
175 Berson A, Freneaux E, Larrey D et al.: Possible role of HLA in hepatotoxicity. An exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol.20(3),336–342 (1994).Crossref, Medline, CAS, Google Scholar
176 Andrade RJ, Lucena MI, Alonso A et al.: HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology39(6),1603–1612 (2004).Crossref, Medline, CAS, Google Scholar
177 Johnson GC, Esposito L, Barratt BJ et al.: Haplotype tagging for the identification of common disease genes. Nat. Genet.29(2),233–237 (2001).Crossref, Medline, CAS, Google Scholar
178 de Bakker PI, Yelensky R, Pe’er I, Gabriel SB, Daly MJ, Altshuler D: Efficiency and power in genetic association studies. Nat. Genet.37(11),1217–1223 (2005).Crossref, Medline, CAS, Google Scholar
179 Davey SG, Ebrahim S, Lewis S, Hansell AL, Palmer LJ, Burton PR: Genetic epidemiology and public health: hope, hype, and future prospects. Lancet366(9495),1484–1498 (2005).Crossref, Medline, Google Scholar
180 Hattersley AT, McCarthy MI: What makes a good genetic association study? Lancet366(9493),1315–1323 (2005).Crossref, Medline, Google Scholar
181 Romeo S, Kotzlitina J, Xing C et al.: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat. Genet.40(12),1461–1465 (2008).Crossref, Medline, CAS, Google Scholar
182 Roses AD: Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat. Rev. Genet.5(9),645–656 (2004).Crossref, Medline, CAS, Google Scholar
183 Kindmark A, Jawaid A, Harbron CG et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J.8(3),186–195 (2008).Crossref, Medline, CAS, Google Scholar
184 Harrill AH, Watkins PB, Su S et al.: Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome. Res. (2009) (Epub ahead of print).Medline, Google Scholar
185 Andrade RJ, Lucena MI, Fernández MC et al.: Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology129(2),512–521 (2005).Crossref, Medline, Google Scholar
201 International HapMap Project http://www. hapmap.org/ (Accessed 18 July, 2009)Google Scholar

Vol. 10, No. 9

Metrics

Downloaded 1,075 times

History

Published online 17 September 2009

Published in print September 2009

Information

Keywords

Acknowledgement

We thank Peter Turner for reviewing the English style of the manuscript.

Financial & competing interests disclosure

The studies on which this article is based have been funded by research grants from the Agencia Española de Medicamentos, Fondo de Investigacion Sanitaria FIS PI 07/0980 and EC07/90910 and from Boehringer-Ingelheim, Barcelona, Spain. CIBERehd is funded by the Instituto de Salud Carlos III. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

PDF download